{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:44:39Z","timestamp":1782258279567,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin\/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and\/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00125-024-06100-z","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:02:53Z","timestamp":1708434173000},"page":"974-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-5028","authenticated-orcid":false,"given":"Sophie","family":"B\u00e9liard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-4095","authenticated-orcid":false,"given":"Florian","family":"Mourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-3280","authenticated-orcid":false,"given":"Ren\u00e9","family":"Val\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"issue":"2","key":"6100_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"issue":"21","key":"6100_CR2","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195\u20132207. https:\/\/doi.org\/10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"issue":"9716","key":"6100_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735\u2013742. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6","journal-title":"Lancet"},{"issue":"10059","key":"6100_CR4","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532\u20132561. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"issue":"Suppl C","key":"6100_CR5","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","volume":"18","author":"R Ferrari","year":"2016","unstructured":"Ferrari R, Aguiar C, Alegria E et al (2016) Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl 18(Suppl C):C2\u2013C12. https:\/\/doi.org\/10.1093\/eurheartj\/suw009","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"6100_CR6","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verges","year":"2015","unstructured":"Verges B (2015) Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58(5):886\u2013899. https:\/\/doi.org\/10.1007\/s00125-015-3525-8","journal-title":"Diabetologia"},{"issue":"4","key":"6100_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118(4):547\u2013563. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249","journal-title":"Circ Res"},{"issue":"9607","key":"6100_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"C Cholesterol Treatment Trialists","year":"2008","unstructured":"Cholesterol Treatment Trialists C, Kearney PM, Blackwell L et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607):117\u2013125. https:\/\/doi.org\/10.1016\/S0140-6736(08)60104-X","journal-title":"Lancet"},{"issue":"9716","key":"6100_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735\u2013742. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6","journal-title":"Lancet"},{"issue":"3","key":"6100_CR10","doi-asserted-by":"publisher","first-page":"101749","DOI":"10.1016\/j.beem.2023.101749","volume":"37","author":"N Sattar","year":"2023","unstructured":"Sattar N (2023) Statins and diabetes: what are the connections? Best Pract Res Clin Endocrinol Metab 37(3):101749. https:\/\/doi.org\/10.1016\/j.beem.2023.101749","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"6100_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11883-019-0780-z","volume":"21","author":"R Carmena","year":"2019","unstructured":"Carmena R, Betteridge DJ (2019) Diabetogenic action of statins: mechanisms. Curr Atheroscler Rep 21(6):23. https:\/\/doi.org\/10.1007\/s11883-019-0780-z","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"6100_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH (2019) Statin toxicity. Circ Res 124(2):328\u2013350. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312782","journal-title":"Circ Res"},{"issue":"17","key":"6100_CR13","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","volume":"118","author":"M Ruscica","year":"2023","unstructured":"Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A (2023) Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res 118(17):3288\u20133304. https:\/\/doi.org\/10.1093\/cvr\/cvac020","journal-title":"Cardiovasc Res"},{"issue":"11","key":"6100_CR14","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1161\/ATVBAHA.121.316159","volume":"41","author":"F Abbasi","year":"2021","unstructured":"Abbasi F, Lamendola C, Harris CS et al (2021) Statins are associated with increased insulin resistance and secretion. Arterioscler Thromb Vasc Biol 41(11):2786\u20132797. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316159","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9965","key":"6100_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","volume":"385","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, Preiss D, Kuchenbaecker KB et al (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385(9965):351\u2013361. https:\/\/doi.org\/10.1016\/S0140-6736(14)61183-1","journal-title":"Lancet"},{"issue":"2","key":"6100_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","volume":"241","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K et al (2015) Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241(2):409\u2013418. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.06.001","journal-title":"Atherosclerosis"},{"issue":"1","key":"6100_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","volume":"21","author":"M Banach","year":"2022","unstructured":"Banach M, Surma S, Reiner Z et al (2022) Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol 21(1):263. https:\/\/doi.org\/10.1186\/s12933-022-01684-5","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6100_CR18","doi-asserted-by":"publisher","first-page":"e000134","DOI":"10.1136\/bmjmed-2022-000134","volume":"1","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhan S, Du H et al (2022) Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJ Med 1(1):e000134. https:\/\/doi.org\/10.1136\/bmjmed-2022-000134","journal-title":"BMJ Med"},{"issue":"15","key":"6100_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA et al (2018) Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137(15):1571\u20131582. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030950","journal-title":"Circulation"},{"issue":"8","key":"6100_CR20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M et al (2019) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 7(8):618\u2013628. https:\/\/doi.org\/10.1016\/S2213-8587(19)30158-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6100_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD et al (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5(12):941\u2013950. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"6100_CR22","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD et al (2016) Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 375(22):2144\u20132153. https:\/\/doi.org\/10.1056\/NEJMoa1604304","journal-title":"N Engl J Med"},{"key":"6100_CR23","doi-asserted-by":"publisher","unstructured":"Guedeney P, Giustino G, Sorrentino S et al (2022) Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 43(7):e17\u2013e25. https:\/\/doi.org\/10.1093\/eurheartj\/ehz430","DOI":"10.1093\/eurheartj\/ehz430"},{"issue":"15","key":"6100_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD et al (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146(15):1109\u20131119. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620","journal-title":"Circulation"},{"issue":"2","key":"6100_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray KK, Raal FJ, Kallend DG et al (2023) Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 44(2):129\u2013138. https:\/\/doi.org\/10.1093\/eurheartj\/ehac594","journal-title":"Eur Heart J"},{"issue":"15","key":"6100_CR26","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376(15):1430\u20131440. https:\/\/doi.org\/10.1056\/NEJMoa1615758","journal-title":"N Engl J Med"},{"issue":"1","key":"6100_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Teoh H, Kallend D et al (2019) Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care 42(1):173\u2013176. https:\/\/doi.org\/10.2337\/dc18-1491","journal-title":"Diabetes Care"},{"issue":"48","key":"6100_CR28","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA et al (2022) Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 43(48):5047\u20135057. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615","journal-title":"Eur Heart J"},{"issue":"2","key":"6100_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ et al (2023) Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol 11(2):109\u2013119. https:\/\/doi.org\/10.1016\/S2213-8587(22)00353-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6100_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","volume":"14","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL et al (2020) Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol 14(5):649-659 e646. https:\/\/doi.org\/10.1016\/j.jacl.2020.08.009","journal-title":"J Clin Lipidol"},{"issue":"5","key":"6100_CR31","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","volume":"24","author":"LA Leiter","year":"2022","unstructured":"Leiter LA, Banach M, Catapano AL et al (2022) Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 24(5):868\u2013880. https:\/\/doi.org\/10.1111\/dom.14645","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"6100_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL et al (2019) Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med 380(11):1033\u20131042. https:\/\/doi.org\/10.1056\/NEJMoa1806747","journal-title":"N Engl J Med"},{"issue":"15","key":"6100_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388(15):1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024","journal-title":"N Engl J Med"},{"issue":"40","key":"6100_CR34","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R et al (2023) Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J 44(40):4272\u20134280. https:\/\/doi.org\/10.1093\/eurheartj\/ehad596","journal-title":"Eur Heart J"},{"issue":"32","key":"6100_CR35","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","volume":"38","author":"C Landlinger","year":"2017","unstructured":"Landlinger C, Pouwer MG, Juno C et al (2017) The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J 38(32):2499\u20132507. https:\/\/doi.org\/10.1093\/eurheartj\/ehx260","journal-title":"Eur Heart J"},{"issue":"5","key":"6100_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","volume":"36","author":"X Wang","year":"2016","unstructured":"Wang X, Raghavan A, Chen T et al (2016) CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report. Arterioscler Thromb Vasc Biol 36(5):783\u2013786. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307227","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9500","key":"6100_CR37","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500):1849\u20131861. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2","journal-title":"Lancet"},{"issue":"9545","key":"6100_CR38","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(06)69594-9","volume":"368","author":"A Keech","year":"2006","unstructured":"Keech A, Simes J, Barter P et al (2006) Correction to the FIELD study report. Lancet 368(9545):1415. https:\/\/doi.org\/10.1016\/S0140-6736(06)69594-9","journal-title":"Lancet"},{"issue":"17","key":"6100_CR39","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563\u20131574. https:\/\/doi.org\/10.1056\/NEJMoa1001282","journal-title":"N Engl J Med"},{"issue":"21","key":"6100_CR40","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC et al (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387(21):1923\u20131934. https:\/\/doi.org\/10.1056\/NEJMoa2210645","journal-title":"N Engl J Med"},{"issue":"9729","key":"6100_CR41","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J et al (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729):1875\u20131884. https:\/\/doi.org\/10.1016\/S0140-6736(10)60656-3","journal-title":"Lancet"},{"key":"6100_CR42","doi-asserted-by":"publisher","unstructured":"Sacks FM, Carey VJ, Fruchart JC (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363(7):692\u2013694; author reply 694-695. https:\/\/doi.org\/10.1056\/NEJMc1006407","DOI":"10.1056\/NEJMc1006407"},{"issue":"Suppl 1","key":"6100_CR43","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S158\u2013S190. https:\/\/doi.org\/10.2337\/dc23-S010","journal-title":"Diabetes Care"},{"issue":"1","key":"6100_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"3","key":"6100_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung T, Halsey J, Kromhout D et al (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 3(3):225\u2013234. https:\/\/doi.org\/10.1001\/jamacardio.2017.5205","journal-title":"JAMA Cardiol"},{"issue":"16","key":"6100_CR46","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Group ASC, Bowman L, Mafham M et al (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379(16):1540\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1804989","journal-title":"N Engl J Med"},{"issue":"22","key":"6100_CR47","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M et al (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324(22):2268\u20132280. https:\/\/doi.org\/10.1001\/jama.2020.22258","journal-title":"JAMA"},{"issue":"1","key":"6100_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"issue":"9","key":"6100_CR49","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","volume":"19","author":"J Boren","year":"2022","unstructured":"Boren J, Taskinen MR, Bjornson E, Packard CJ (2022) Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol 19(9):577\u2013592. https:\/\/doi.org\/10.1038\/s41569-022-00676-y","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"6100_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacl.2017.02.012","volume":"11","author":"M Maraninchi","year":"2017","unstructured":"Maraninchi M, Padilla N, Beliard S et al (2017) Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects. J Clin Lipidol 11(2):495-506 e493. https:\/\/doi.org\/10.1016\/j.jacl.2017.02.012","journal-title":"J Clin Lipidol"},{"issue":"3","key":"6100_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","volume":"43","author":"HN Ginsberg","year":"2023","unstructured":"Ginsberg HN, Goldberg IJ (2023) Broadening the scope of dyslipidemia therapy by targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arterioscler Thromb Vasc Biol 43(3):388\u2013398. https:\/\/doi.org\/10.1161\/ATVBAHA.122.317966","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"6100_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD et al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 381(6):531\u2013542. https:\/\/doi.org\/10.1056\/NEJMoa1715944","journal-title":"N Engl J Med"},{"issue":"5","key":"6100_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q et al (2021) Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(5):264\u2013275. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6100_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J et al (2022) Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN study. J Clin Lipidol 16(6):833\u2013849. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","journal-title":"J Clin Lipidol"},{"issue":"6","key":"6100_CR55","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S et al (2019) Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 140(6):470\u2013486. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039107","journal-title":"Circulation"},{"issue":"14","key":"6100_CR56","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES et al (2022) Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 43(14):1401\u20131412. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820","journal-title":"Eur Heart J"},{"issue":"9","key":"6100_CR57","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","volume":"23","author":"SA Khetarpal","year":"2017","unstructured":"Khetarpal SA, Zeng X, Millar JS et al (2017) A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med 23(9):1086\u20131094. https:\/\/doi.org\/10.1038\/nm.4390","journal-title":"Nat Med"},{"issue":"18","key":"6100_CR58","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR et al (2022) Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation 145(18):1377\u20131386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266","journal-title":"Circulation"},{"issue":"9","key":"6100_CR59","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R et al (2023) RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med 29(9):2216\u20132223. https:\/\/doi.org\/10.1038\/s41591-023-02494-2","journal-title":"Nat Med"},{"issue":"10165","key":"6100_CR60","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal A, Charles ED, Neuschwander-Tetri BA et al (2019) Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392(10165):2705\u20132717. https:\/\/doi.org\/10.1016\/S0140-6736(18)31785-9","journal-title":"Lancet"},{"issue":"7","key":"6100_CR61","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt DL, Bays HE, Miller M et al (2023) The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 29(7):1782\u20131792. https:\/\/doi.org\/10.1038\/s41591-023-02427-z","journal-title":"Nat Med"},{"issue":"1","key":"6100_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/clinchem\/hvaa148","volume":"67","author":"AR Tall","year":"2021","unstructured":"Tall AR (2021) HDL in morbidity and mortality: a 40+ year perspective. Clin Chem 67(1):19\u201323. https:\/\/doi.org\/10.1093\/clinchem\/hvaa148","journal-title":"Clin Chem"},{"issue":"8","key":"6100_CR63","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ et al (2022) Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med 28(8):1672\u20131678. https:\/\/doi.org\/10.1038\/s41591-022-01936-7","journal-title":"Nat Med"},{"issue":"6","key":"6100_CR64","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","volume":"44","author":"W Masson","year":"2018","unstructured":"Masson W, Lobo M, Siniawski D et al (2018) Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab 44(6):508\u2013513. https:\/\/doi.org\/10.1016\/j.diabet.2018.02.005","journal-title":"Diabetes Metab"},{"issue":"6","key":"6100_CR65","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas K, Navar AM, Kastelein JJP (2022) The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 8(6):622\u2013632. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"39","key":"6100_CR66","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925\u20133946. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"},{"issue":"12","key":"6100_CR67","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.acvd.2021.10.009","volume":"114","author":"V Durlach","year":"2021","unstructured":"Durlach V, Bonnefont-Rousselot D, Boccara F et al (2021) Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Societe Francophone d\u2019Atherosclerose (NSFA). Arch Cardiovasc Dis 114(12):828\u2013847. https:\/\/doi.org\/10.1016\/j.acvd.2021.10.009","journal-title":"Arch Cardiovasc Dis"},{"issue":"11","key":"6100_CR68","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11883-022-01060-4","volume":"24","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Kraaijenhof JM, Stroes ESG (2022) Lp(a): a new pathway to target? Curr Atheroscler Rep 24(11):831\u2013838. https:\/\/doi.org\/10.1007\/s11883-022-01060-4","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"6100_CR69","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","volume":"56","author":"S Mora","year":"2010","unstructured":"Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM (2010) Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 56(8):1252\u20131260. https:\/\/doi.org\/10.1373\/clinchem.2010.146779","journal-title":"Clin Chem"},{"issue":"1","key":"6100_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","volume":"16","author":"E Paige","year":"2017","unstructured":"Paige E, Masconi KL, Tsimikas S et al (2017) Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 16(1):38. https:\/\/doi.org\/10.1186\/s12933-017-0520-z","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"6100_CR71","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P et al (2019) Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 74(24):2982\u20132994. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.019","journal-title":"J Am Coll Cardiol"},{"key":"6100_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","volume":"349","author":"C Lamina","year":"2022","unstructured":"Lamina C, Ward NC (2022) Lipoprotein (a) and diabetes mellitus. Atherosclerosis 349:63\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.016","journal-title":"Atherosclerosis"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06100-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T11:03:11Z","timestamp":1714388591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6100"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06100-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors received no funding linked to this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SB received honoraria from Amarin, Amgen, Amryt, Novartis, Sanofi and Ultragenyx for lectures and for boards (Novartis, Ultragenyx) and participated in trials for Akcea, Ionis, Amgen, Novartis and Sanofi-Regeneron. RV received honoraria from Amarin, Amgen, Arrowhead, Servier and Sanofi for lectures and participated in trials for Akcea, Ionis, Amgen, Novartis and Sanofi-Regeneron. FM participated in trials for Akcea, Ionis, Amgen, Novartis and Sanofi-Regeneron.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}